Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Steglujan
| Field | Information |
|---|---|
| Medication Name | Steglujan |
| Generic Name | Ertugliflozin/Sitagliptin |
| Purpose | To lower blood sugar levels in adults with type 2 diabetes mellitus, along with diet and exercise. |
| Mechanism of Action | Ertugliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys, increasing glucose excretion. Sitagliptin is a DPP-4 inhibitor that increases incretin levels, stimulating insulin release and decreasing glucagon secretion. |
| Dosage Forms | Oral tablets |
| Available Strengths | 5 mg/100 mg, 15 mg/100 mg |
| Dosage Frequency | Once daily |
| Common Side Effects | Urinary tract infections, female genital mycotic infections, nasopharyngitis, increased urination |
| Serious Side Effects | Ketoacidosis, kidney problems, severe allergic reactions, pancreatitis, low blood sugar (hypoglycemia) when used with other diabetes medications |
| Drug Interactions | Insulin and insulin secretagogues (sulfonylureas) may increase the risk of hypoglycemia. Rifampin, phenytoin, carbamazepine, and other CYP3A4 inducers may decrease ertugliflozin levels. Digoxin levels may be increased. |
| Important Notes | Steglujan is not for people with type 1 diabetes or diabetic ketoacidosis. Patients should monitor for signs of ketoacidosis (difficulty breathing, nausea, vomiting, abdominal pain, confusion, unusual fatigue or sleepiness). Use with caution in patients with renal impairment. |
| Storage | Store at room temperature between 68°F to 77°F (20°C to 25°C) away from moisture and light. |
| Missed Dose | Take it as soon as you remember. If it is close to your next dose, skip the missed dose and take your next dose at the regular time. Do not double the dose to catch up. |
| Alternatives | Januvia (sitagliptin), Farxiga (dapagliflozin), Jardiance (empagliflozin), Metformin |
Steglujan Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Januvia (sitagliptin) | DPP-4 inhibitor | Increases incretin levels to stimulate insulin release and decrease glucagon. |
| Farxiga (dapagliflozin) | SGLT2 inhibitor | Reduces glucose reabsorption in the kidneys, increasing glucose excretion. |
| Jardiance (empagliflozin) | SGLT2 inhibitor | Reduces glucose reabsorption in the kidneys, increasing glucose excretion. |
| Metformin | Biguanide; decreases hepatic glucose production and improves insulin sensitivity | Often used as a first-line treatment for type 2 diabetes. |
Steglujan Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Urinary tract infections | Ketoacidosis (difficulty breathing, nausea, vomiting, abdominal pain, confusion) |
| Female genital mycotic infections | Kidney problems |
| Nasopharyngitis (common cold) | Severe allergic reactions (rash, itching, swelling, difficulty breathing) |
| Increased urination | Pancreatitis (severe abdominal pain that may radiate to the back) |
| Headache | Low blood sugar (hypoglycemia) when used with other diabetes medications (sweating, shaking, confusion) |
Steglujan Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Type 2 Diabetes | 5 mg/100 mg once daily | May be increased to 15 mg/100 mg once daily based on glycemic control and tolerability. | Take once daily in the morning. Can be taken with or without food. |
